About ATRO Medical BV

ATRO Medical B.V. is an innovative medical device company that was founded in 2016. The first product under development is the Trammpolin® meniscus prosthesis. The meniscus is an important shock absorber in the knee joint. Damage and wear of the meniscus are important causes of osteoarthritis of the knee. Trammpolin® intends to replace the damaged meniscus, with the aim of restoring the shock absorbing function of the meniscus by acting as a joint spacer.

The company is addressing a large unmet medical need, as the number of patients with knee pain caused by a meniscectomy increase. These patients gradually develop osteoarthritis, resulting in pain and reduced mobility. Current treatment options for these patients are limited with distinct drawbacks. The Trammpolin® meniscus prosthesis aims to provide a cost-­effective solution for meniscus replacements and to fill the gap in treatment options between meniscus tear surgical repair and total knee replacement.

go to main content
Radboudumc and partners Spin-off companies ATRO Medical BV

About ATRO Medical BV

The focus of ATRO Medical BV is to develop and commercialize an anatomical shaped prostheses for joint injuries. read more

ATRO Medical BV details

  • CEO: Tony van Tienen
  • CIO: Maarten van der Zanden
  • COO: Anita Brinks
  • Affliated department: Orthopedics
  • Researcher: Tony van Tienen
  • Year of incorporation: 2016
ATRO Medical BV website

News

Boosting the startup ecosystem in Nijmegen!

22 June 2023

TechleapNL, Radboud university, Radboudumc and the municipality of Nijmegen hosted a successful event where innovative health and hightech startups shared their view on the challenges and opportunities for the local startup ecosystem.

EU grant awarded to development of meniscus prosthesis € 2.5 million for ATRO Medical

8 June 2022 The Dutch startup works on the first anatomical meniscus prostheses for patients with chronic knee pain. Their ground-breaking innovation continues to attract international attention, paving the way towards full-scale healthcare implementation.

ATRO Medical closes a new financing round for the Trammpolin® meniscus prosthesis

17 December 2021 ATRO Medical announces the successful closure of a €1.9 million financing round to complete the AIR2 clinical study.

Survey of patients to address knee pain from removed meniscus

19 November 2021 Patients with persistent knee pain after meniscus removal can participate at three locations in the Netherlands in the AIR2 study by ATRO Medical, a spin-off of the Radboudumc and DSM.

ATRO Medical, Radboudumc and Samaplast develop new meniscus prosthesis Consortium receives EUROSTARS grant for innovative project

16 July 2020 An international consortium led by ATRO Medical, a spin-off of Radboudumc and DSM, will receive € 800,000 European funding for an innovation aimed at patients with knee osteoarthritis. These patients often suffer from cartilage wear due to a meniscus that no longer works properly.

ATRO Medical's meniscus prothesis receives FDA Breakthrough Designation

22 January 2020 The Trammpolin meniscus is an implant that aims at reducing knee pain and improve mobility.

What we do

spin-off companies
contact
news